LOS ANGELES, CALIFORNIA--(Marketwired - April 22, 2015) -


Convalo Health International, Corp. ("Convalo" or the "Company") (TSX VENTURE:CXV), an acquisition-oriented company focused on rolling up the US addiction rehabilitation market, is pleased to announce that it has closed its previously announced bought deal private placement offering (the "Offering"). Mackie Research Capital Corporation was lead underwriter and sole bookrunner on behalf of a syndicate of underwriters including Beacon Securities Limited (the "Underwriters"), whereby the Underwriters purchased 43,125,000 units (the "Units") of the Company at a price of $0.40 per Unit, for gross proceeds to the Company of $17,250,000, which included the full exercise of the over-allotment option of 5,625,000 Units.

The securities issued under the Offering are subject to a hold period which will expire four months and one day from the date of closing, being August 23, 2015. The net proceeds from the Offering will be used by Convalo for acquisition purposes and general working capital.

In consideration for their services, the Underwriters received a cash commission of 5.0% of the gross proceeds of the Offering, and have received such number of compensation options exercisable into Units, as is equal to 5.0% of the Units issued in the Offering.

About Convalo

Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In May 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. Since May, the business has operated under the brand name BLVD Centers (www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively- oriented, meditation/mindfulness, trauma and LGBT affirmative.

Forward Looking Statements

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Convalo and anticipated events or results, are assumptions based on beliefs of Convalo's senior management as well as information currently available to it. While these assumptions were considered reasonable by Convalo at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue acquisitions, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

Contact Information:

Convalo Health International, Corp.
Dennis Wilson
Corporate Affairs
Email: investorinfo@convalohealth.com